Yuli 2022: Dangane da binciken da aka yi kwanan nan wanda Binciken Emergen ya gudanar, kasuwar duniya don maganin CAR T-cells ya kai dala biliyan 1.29 a cikin 2021 kuma ana sa ran yin rijistar kudaden shiga CAGR na kashi 24.9 a tsawon lokacin hasashen. Haɓaka cutar sankara a duk faɗin duniya da kuma karuwar mace-mace da cutar kansa ke haifarwa ana tsammanin za su kasance farkon abubuwan haɓakar kudaden shiga a cikin kasuwar maganin ƙwayoyin cuta ta CAR-T ta duniya a tsawon lokacin hasashen. Fadada ayyukan gwaji na asibiti a cikin hanzari, haɓaka haɗe-haɗe da saye, da sha'awar sadaukarwar jama'a na farko duk abubuwan da ke ba da gudummawa ga haɓakar kudaden shiga a cikin kasuwar maganin CAR T-cell ta duniya.
The primary objective of the report is to provide an overview of the market, including product scope, growth prospects, and potential risks. In-depth information about each participant in the global CAR T-Cell Far market, including that participant’s global standing, financial status, product launch, and business expansion plans, is included in the report. The participants in the market are concentrating their efforts on the creation of a variety of strategies, including partnerships, mergers and acquisitions, joint ventures, product launches, and investments in research and development.
According to the findings of the study, there are certain types of dangers and difficulties that can serve as an obstacle for a company. Granularity can be added to the overall research by performing an in-depth analysis of the CAR T-Cell Far market in the context of various aspects of the larger environment, such as the social, political, economic, and technological settings. In addition, the study generates real-time data on essential aspects such as sales, profits, gross margin, and growth prospects to demonstrate how going forward the company will see a significant upswing in its performance.
Karin wasu muhimman bayanai daga rahoton sun nuna cewa
In 2021, the segment of diffuse large B-cell linzoma was responsible for the majority of the rapid revenue share. A cancer of the lymphatic system, which is an essential component of the immune system, called diffuse large B-cell lymphoma has a rapid growth rate. It has an effect on the blood cells that generate antibodies, which are used to fight infections. In certain instances, DLBCL can be cured. The majority of patients suffering from DLBCL have a favourable response to initial treatments such as chemotherapy. In the case of some people, the illness either becomes resistant to treatment, which means that it no longer responds to it, or it relapses, which means that it returns after treatment has been completed. These patients may be candidates for treatment with chimeric antigen receptor T-cell far, which utilises the patient’s own immune cells in the fight against DLBCL. T-cells are taken out of the patient’s blood, modified in the laboratory with so-called chimeric antigen receptors that help in recognising and destroying cancer cells, and then reintroduced into the patient’s blood again. This process is repeated several times.
In 2021, the hospital segment was responsible for a fair amount of the total revenue. The CAR T-cell therapy will reprogramme the patient’s T-cells so that they will target the antigens produced by the tumour. CAR T-cell therapy has shown full remission rates of 80 to 90 percent in younger patients with B-cell acute lymphoblastic leukaemia, and it has shown a full remission rate of 40 percent in patients with symptomatic B-cell non-Hodgkin lymphomas who have failed several prior lines of therapy. Both of these patient populations have B-cell acute lymphoblastic leukaemia.
Ana ci gaba da bincika manyan kamfanonin da ke aiki a kasuwa a cikin wannan rahoto, kamar yadda bayanan kamfanonin su, kayan aikin samfuri, dabarun faɗaɗawa, da ƙawance masu alaƙa. Wasu misalan waɗannan nau'ikan ƙawance sun haɗa da haɗaka da saye, haɗin gwiwa, da haɗin gwiwa. Baya ga wannan, yana ba da bayanai game da nasarorin da kamfani ya samu da kuma yanayin kuɗi, da kuma hangen nesa game da isa ga kasuwa da matsayin kamfani a duniya.
Kamfanoni da aka bayyana a cikin kasuwar CAR T-Cell Therapy na duniya:
Novartis AG, Pfizer Inc., CARsgen Therapeutics Co., Ltd, Kamfanin Daiichi Sankyo, Limited, Kamfanin Bristol-Myers Squibb, Astellas Pharma Inc., BioNTech SE, Biocad, F. Hoffmann-La Roche Ltd., da Eli Lilly da Kamfanin .
Kara karantawa kan rahoton kasuwar CAR T-Cell Therapy na duniya a: https://www.emergenresearch.com/industry-report/car-t-cell-therapy-market
